tiprankstipranks
Trending News
More News >
Inhibikase Therapeutics (IKT)
NASDAQ:IKT

Inhibikase Therapeutics (IKT) Revenue

Compare
380 Followers

Inhibikase Therapeutics Revenue

Inhibikase Therapeutics had a revenue of 0.00 in the quarter ending Sep 30, 2025, with ―. This bring the company's revenue in the last twelve months to 0.00, Decreased ―. In the fiscal year ending Dec 31, 2024, Inhibikase Therapeutics had annual revenue of 0.00 with -100.00% growth.
Revenue (ttm)
0.00
Revenue Growth
-100.00%
P/S Ratio
Revenue/Employee
$0
Employees
15
Market Cap
$221.92M

Revenue Chart

Revenue History
Fiscal End Date
Revenue
Change
Growth
Dec 31, 2024
-260.50K-100.00%
Dec 31, 2023
260.50K137.06K+111.03%
Mar 31, 2023
123.44K-2.98M-96.02%
Mar 31, 2022
3.10M2.40M+343.92%
Mar 31, 2021
698.47K-424.27K-37.79%
Dec 31, 2019
1.12M-2.92M-72.22%
Dec 31, 2018
4.04M1.98M+96.07%
Dec 31, 2017
2.06M